Related content

Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide

By Osoba D.   Brada M.   Yung W.K.A.   Prados M.D.  

European Journal of Cancer, Vol. 36, Iss. 14, 2000-09 ,pp. : 1788-1795

Elsevier

Access to resources Recommend Favorite

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

By                      

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 654-658

Spandidos Publications

Access to resources Recommend Favorite

Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma

By          

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1260-1270

Spandidos Publications

Access to resources Recommend Favorite

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

By Fiano Valentina   Trevisan Morena   Trevisan Elisa   Senetta Rebecca   Castiglione Anna   Sacerdote Carlotta   Gillio-Tos Anna   Marco Laura   Grasso Chiara   Magistrello Michela   Tondat Fabrizio   Rudà Roberta   Cassoni Paola   Soffietti Riccardo   Merletti Franco  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 347-357

Springer Publishing Company

Access to resources Recommend Favorite

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

By Balañá Carmen  

Clinical and Translational Oncology, Vol. 13, Iss. 9, 2011-09 ,pp. : 677-685

Springer Publishing Company

Access to resources Recommend Favorite